Literature DB >> 17719933

Primary sclerosing cholangitis in childhood is associated with abnormalities in cystic fibrosis-mediated chloride channel function.

Harpreet Pall1, Julian Zielenski, Maureen M Jonas, Deborah A DaSilva, Kimberly M Potvin, Xiao-Wei Yuan, Qiuju Huang, Steven D Freedman.   

Abstract

OBJECTIVE: To determine whether primary sclerosing cholangitis (PSC) in childhood is associated with abnormalities in cystic fibrosis transmembrane conductance regulator (CFTR). STUDY
DESIGN: Subjects with PSC diagnosed in childhood (n = 20) were recruited from Children's Hospital. Subjects had testing with sweat chloride concentration, nasal transmembrane potential difference, and extensive genetic analysis of the CFTR gene. Disease control subjects consisted of 14 patients with inflammatory bowel disease alone and no liver disease. t tests were performed to determine statistical significance.
RESULTS: In the PSC group, CFTR chloride channel function (deltaChloride free + isoproterenol) was markedly diminished at -8.6 +/- 8.2 mV (reference range: -24.6 +/- 10.4 mV). In contrast, disease control subjects had normal function, at -17.8 +/- 9.7 mV (P = .008). Sweat chloride concentration in subjects with PSC was greater than in disease control subjects (20.8 +/- 3.4 mmol/L vs 12.0 +/- 1.6 mmol/L, P = .045). Comprehensive CFTR genotyping revealed that 5 of 19 (26.3%) subjects with PSC had a CFTR mutation or variant, compared with 6 of 14 (42.9%) disease control subjects.
CONCLUSIONS: There is a high prevalence of CFTR-mediated ion transport dysfunction in subjects with childhood PSC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17719933     DOI: 10.1016/j.jpeds.2007.03.062

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  13 in total

Review 1.  Management of primary sclerosing cholangitis: conventions and controversies.

Authors:  Natasha Chandok; Gideon M Hirschfield
Journal:  Can J Gastroenterol       Date:  2012-05       Impact factor: 3.522

2.  The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis - a pilot study.

Authors:  C R Martin; P G Blanco; J C Keach; J L Petz; M M Zaman; K R Bhaskar; J E Cluette-Brown; S Gautam; S Sheth; N H Afdhal; K D Lindor; S D Freedman
Journal:  Aliment Pharmacol Ther       Date:  2011-11-30       Impact factor: 8.171

3.  CFTR dysfunction predisposes to fibrotic liver disease in a murine model.

Authors:  Camilia R Martin; Munir M Zaman; Gyanprakash A Ketwaroo; Abdul Q Bhutta; Emmanuel Coronel; Yury Popov; Detlef Schuppan; Steven D Freedman
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-06-07       Impact factor: 4.052

4.  Investigating the genetic profile of familial atypical cystic fibrosis patients (DeltaF508-CFTR) with neonatal biliary atresia.

Authors:  Omar Rabab'h; Dunia Aburizeg; Eyad Altamimi; Lynn Akasheh; Zain Dardas; Luma Srour; Heyam Awad; Bilal Azab
Journal:  J Appl Genet       Date:  2022-10-07       Impact factor: 2.653

Review 5.  Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.

Authors:  Michael Trauner; Peter Fickert; Emina Halilbasic; Tarek Moustafa
Journal:  Wien Med Wochenschr       Date:  2008

6.  Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis.

Authors:  Johannes R Hov; Verena Keitel; Jon K Laerdahl; Lina Spomer; Eva Ellinghaus; Abdou ElSharawy; Espen Melum; Kirsten M Boberg; Thomas Manke; Tobias Balschun; Christoph Schramm; Annika Bergquist; Tobias Weismüller; Daniel Gotthardt; Christian Rust; Liesbet Henckaerts; Clive M Onnie; Rinse K Weersma; Martina Sterneck; Andreas Teufel; Heiko Runz; Adolf Stiehl; Cyriel Y Ponsioen; Cisca Wijmenga; Morten H Vatn; Pieter C F Stokkers; Severine Vermeire; Christopher G Mathew; Benedicte A Lie; Ulrich Beuers; Michael P Manns; Stefan Schreiber; Erik Schrumpf; Dieter Häussinger; Andre Franke; Tom H Karlsen
Journal:  PLoS One       Date:  2010-08-25       Impact factor: 3.240

Review 7.  Background and Epidemiology.

Authors:  Don B Sanders; Aliza K Fink
Journal:  Pediatr Clin North Am       Date:  2016-08       Impact factor: 3.278

Review 8.  Patterns of gastrointestinal disease associated with mutations of CFTR.

Authors:  Michael Wilschanski
Journal:  Curr Gastroenterol Rep       Date:  2008-06

9.  Primary Sclerosing Cholangitis: Current and Future Management Strategies.

Authors:  John E Eaton; Jayant A Talwalkar
Journal:  Curr Hepat Rep       Date:  2013-03-01

Review 10.  Cystic fibrosis from the gastroenterologist's perspective.

Authors:  Chee Y Ooi; Peter R Durie
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-01-21       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.